All NotesCorporate LawIntellectual Property Rights (IPR)

IPR

Topic 127 Bilateral Regional Framework

Topic 127 — Bilateral and Regional IP Framework

Beyond multilateral WIPO and TRIPS framework, India's international IP commitments are shaped by bilateral and regional agreements. India has 100+ Bilateral Investment Treaties (BITs) — though many are now under termination/renegotiation. Major free trade agreements (FTAs) and regional frameworks: INDIA-EU FTA (negotiations active 2007-onwards; recent acceleration 2022-2024); INDIA-UK FTA (concluded 2025); INDIA-EFTA Trade and Economic Partnership Agreement (TEPA — signed 10 March 2024; entry into force 1 December 2025); INDIA-AUSTRALIA Comprehensive Economic Cooperation Agreement (CECA) (Interim Trade Agreement IECA effective 29 December 2022; full CECA negotiations); INDIA-UAE Comprehensive Economic Partnership Agreement (CEPA) (effective 1 May 2022); INDIA-MAURITIUS Comprehensive Economic Cooperation and Partnership Agreement (CECPA) (effective 1 April 2021). India's strategic position: WITHDREW from REGIONAL COMPREHENSIVE ECONOMIC PARTNERSHIP (RCEP) in November 2019 — primarily over IP TRIPS-Plus + agricultural concerns. CEPA with UAE includes IP provisions but balanced. EFTA TEPA includes commitments on patents, trademarks, designs, GIs, copyright. India-EU FTA negotiations focus on TRIPS-Plus issues. Bilateral Investment Treaties — India terminated old BITs in 2016-2019; new model BIT 2016 has narrower scope. The 2024 WIPO Treaty on Genetic Resources + Traditional Knowledge represents new multilateral progress. India's strategic approach: PRESERVE TRIPS flexibilities; OPPOSE TRIPS-Plus; STRENGTHEN South-South cooperation; PROMOTE Indian IP interests abroad. The Mediation Act 2023 + Arbitration and Conciliation (Amendment) Act 2024 provide frameworks for international IP disputes. This topic walks through India's bilateral and regional IP framework — major agreements, India's strategic position, and emerging considerations.

1. India's Strategic Framework

A. Multi-Layered International IP Strategy

India's International IP Approach

1. WTO TRIPS · Foundational compliance. · TRIPS flexibilities preservation. · Section 3(d) anti-evergreening. · Section 84 compulsory licensing. 2. WIPO TREATIES · Selective membership. · Paris (1998), Berne (1928), PCT (1998), Madrid Protocol (2013), Hague Geneva Act (2014), Marrakesh (2014), Beijing (2020), Budapest (2001). · NOT Lisbon, WCT, WPPT. 3. BILATERAL TREATIES · India-EU FTA (negotiations). · India-UK FTA (2025). · India-EFTA TEPA (2024-2025). · India-UAE CEPA (2022). · India-Mauritius CECPA (2021). · India-Australia CECA/IECA (2022). 4. REGIONAL FRAMEWORKS · RCEP withdrawn 2019. · South Asian framework limited. · Strategic engagement. 5. POLICY POSITIONS · OPPOSE TRIPS-Plus provisions. · PRESERVE public health flexibilities. · STRENGTHEN South-South cooperation. · PROMOTE Indian IP interests.

2. Bilateral Investment Treaties (BITs)

A. Indian BIT Framework

  • 100+ BITs at peak (~2014).
  • India terminated old BITs from 2016-2019.
  • India's Model BIT 2016 — narrower scope.
  • Balances investor protection with policy autonomy.
  • Limited IP-specific provisions.

B. Model BIT 2016 Key Features

  • "Investment" definition narrowed.
  • Excludes purely financial assets.
  • Local remedies exhaustion required.
  • Limited scope of ISDS (Investor-State Dispute Settlement).
  • Public policy carve-outs strong.
  • IP — limited specific provisions.

3. Major Free Trade Agreements

A. India-UAE Comprehensive Economic Partnership Agreement (CEPA)

India-UAE CEPA (Effective 1 May 2022)

Foundational Framework: · Comprehensive Economic Partnership Agreement. · Effective: 1 May 2022. · Major goods + services + IP framework. IP Provisions: · Trademark cooperation. · Geographical indications mutual recognition. · Copyright cooperation. · Patent cooperation framework. · No TRIPS-Plus (preserved national flexibility). Bilateral Trade: · India's third-largest trading partner. · $80+ billion bilateral trade. · Significant Indian diaspora. · Banking + financial services cooperation. Strategic Significance: · Demonstrates India's balanced FTA approach. · Strong economic engagement without TRIPS-Plus. · Foundation for future FTAs.

B. India-Mauritius CECPA

  • Effective: 1 April 2021.
  • Comprehensive Economic Cooperation and Partnership Agreement.
  • Strategic for South-South cooperation.
  • Includes IP provisions aligned with TRIPS.
  • Tax framework integration.

C. India-Australia CECA / IECA

  • Interim Trade Agreement (IECA) effective: 29 December 2022.
  • Full Comprehensive Economic Cooperation Agreement (CECA) negotiations ongoing.
  • Education + IP + investment provisions.
  • Strategic Indo-Pacific economic engagement.

D. India-EFTA Trade and Economic Partnership Agreement (TEPA)

India-EFTA TEPA (Signed 10 March 2024; Effective 1 December 2025)

EFTA — European Free Trade Association: · Switzerland, Norway, Iceland, Liechtenstein. · Major financial services + R&D economies. Framework: · Signed: 10 March 2024. · Entry into Force: 1 December 2025. · $100 billion investment commitment from EFTA in 15 years. · 1 million jobs commitment. IP Provisions: · Commitments on patents, trademarks, designs, copyright. · Geographical indications mutual recognition. · No major TRIPS-Plus on patent term extension. · Pharmaceutical patents — balanced approach. · Anti-counterfeiting cooperation. Strategic Significance: · India's first major FTA with European economic partner. · Demonstrates IP balanced approach. · Foundation for India-EU FTA framework. · Strong investment commitment.

E. India-UK FTA

  • Negotiations 2022-2024.
  • Concluded: 2025.
  • IP provisions balanced.
  • No TRIPS-Plus on pharmaceutical patents.
  • Anti-counterfeiting cooperation.
  • Significant Indian-UK IP trade.

F. India-EU FTA (Negotiations Active)

  • Negotiations resumed 2022.
  • Major issues: pharmaceutical patents, GIs, data protection.
  • IP TRIPS-Plus debates.
  • Pharmaceutical patent term extension contested.
  • Continued discussions.

4. RCEP — India's Withdrawal

📖 Regional Comprehensive Economic Partnership (RCEP) — India Withdrew November 2019

Background — RCEP — Asia-Pacific regional trade agreement among China, Japan, Korea, ASEAN, Australia, New Zealand. Concluded 15 November 2020.

India's Position — INDIA WITHDREW from negotiations in November 2019 — primarily over: · IP TRIPS-Plus concerns. · Pharmaceutical patent term extension. · Data exclusivity provisions. · Agricultural sector vulnerabilities. · Trade deficit concerns.

Outcome — India did not sign final RCEP agreement.

Significance — India's strategic clarity: · Refusal to compromise TRIPS flexibilities. · Public health considerations. · Strategic autonomy. · Foundation for future trade strategy. · Indian generic pharmaceutical industry preserved.

5. TRIPS-Plus Provisions in FTAs

A. Common TRIPS-Plus Provisions

TRIPS-Plus Provision

Description

India Position

Patent term extension

Beyond 20 years for regulatory delay.

OPPOSED.

Data exclusivity

Pharmaceutical test data protection.

OPPOSED.

Stricter compulsory licensing

Restrictions beyond TRIPS Article 31.

OPPOSED.

Patent linkage

Linking marketing approval to patent status.

OPPOSED.

Border measures expansion

Beyond TRIPS counterfeit/copyright.

CAUTIOUS.

ISP liability

Stronger intermediary obligations.

CAUTIOUS.

GI expansion

Beyond TRIPS Article 22.

CAUTIOUS.

Strict three-step interpretation

Restrictive fair use.

CAUTIOUS.

Investor-State Dispute Settlement

Direct investor lawsuits.

NARROWED 2016.

B. India's Bargaining Position

  • Strong public health considerations.
  • Generic pharmaceutical industry protection.
  • National flexibility preservation.
  • TRIPS commitments + minimal additional obligations.
  • Reciprocity considerations.

6. India's IP Strategic Cooperation

A. South-South Cooperation

  • Technical assistance to LDCs.
  • TRIPS waiver advocacy with developing countries.
  • UN-level IP discussions.
  • BRICS coordination.
  • Indian IP best practices sharing.

B. WIPO Engagement

  • Active in WIPO Standing Committees.
  • IP Genetic Resources + Traditional Knowledge Treaty leadership (May 2024).
  • Patent Law Treaty engagement.
  • Madrid + Hague + PCT system promotion.

C. WTO Engagement

  • TRIPS Council active participation.
  • Doha Declaration follow-up.
  • MC12 Decision (June 2022) on COVID vaccines.
  • Continued vaccine access advocacy.
  • Public health flexibility leadership.

7. Recent Developments (2022-2025)

Development

Year

Significance

India-Mauritius CECPA effective

1 April 2021

South-South cooperation.

India-UAE CEPA effective

1 May 2022

Major balanced FTA.

India-Australia IECA effective

29 December 2022

Indo-Pacific engagement.

MC12 Decision (COVID vaccines)

17 June 2022

TRIPS waiver advocacy success.

Article 31bis post-2017 effectiveness

Ongoing

Multilateral compulsory licensing for export.

India-EFTA TEPA signed

10 March 2024

First major Europe FTA.

WIPO Treaty Genetic Resources

May 2024

New multilateral framework.

India-UK FTA concluded

2025

Major Anglo-Indian framework.

India-EFTA TEPA effective

1 December 2025

Operational framework.

India-EU FTA negotiations

Ongoing

TRIPS-Plus debates.

8. Strategic Considerations

For Indian businesses — eight points

For UAE market, leverage CEPA framework.

For European partners, prepare for EFTA TEPA framework.

For Indo-Pacific, leverage Australia IECA + future CECA.

For UK, leverage 2025 FTA.

For RCEP-style multilateral, monitor developments.

For South-South cooperation, leverage Indian IP framework.

For TRIPS flexibilities, document Indian framework leverage.

For investment protection, navigate Model BIT 2016.

For India's strategic IP positioning — six points

Continue OPPOSING TRIPS-Plus provisions.

Continue PRESERVING public health flexibilities.

Continue STRENGTHENING South-South cooperation.

Continue WIPO + WTO active engagement.

Continue balanced FTA negotiations.

Continue domestic IP framework refinement.

9. Memory Aid — Quick Recall

Quick Recall — Bilateral and Regional Framework

India-Mauritius CECPA effective 1 April 2021.

India-UAE CEPA effective 1 May 2022.

India-Australia IECA effective 29 December 2022.

India-EFTA TEPA signed 10 March 2024; effective 1 December 2025.

India-UK FTA concluded 2025.

India-EU FTA negotiations ongoing.

India WITHDREW from RCEP November 2019.

India's Model BIT 2016 — narrower scope.

India POSITION: oppose TRIPS-Plus; preserve flexibilities; South-South cooperation.

TRIPS-Plus opposed: patent term extension, data exclusivity, stricter CL, patent linkage.

India-UAE: $80+ billion trade.

India-EFTA: $100 billion investment + 1 million jobs commitment.

WIPO Treaty May 2024 — Genetic Resources + Traditional Knowledge.

MC12 Decision June 2022 — COVID vaccines.

🎯 EXAM POINTERS — TOPIC 127

  • India's strategic framework: Multi-layered (WTO TRIPS + WIPO + Bilateral + Regional).
  • India-Mauritius CECPA effective 1 April 2021.
  • India-UAE CEPA — effective 1 May 2022; $80+ billion bilateral trade.
  • India-Australia IECA — Interim Trade Agreement effective 29 December 2022.
  • India-EFTA TEPA — signed 10 March 2024; effective 1 December 2025; $100 billion investment + 1 million jobs commitment.
  • India-UK FTA — concluded 2025.
  • India-EU FTA — negotiations ongoing; TRIPS-Plus contentious.
  • India WITHDREW from RCEP in November 2019.
  • RCEP final agreement signed 15 November 2020 (without India).
  • India's Model BIT 2016 — narrower scope; limited ISDS.
  • India terminated 100+ old BITs from 2016-2019.
  • India OPPOSES TRIPS-Plus: patent term extension; data exclusivity; stricter CL; patent linkage.
  • India PRESERVES public health flexibilities (Section 3(d), 84, 92, 100).
  • India ADVOCATES South-South cooperation.
  • India ACTIVE in WIPO + WTO + UN-level IP discussions.
  • WIPO Treaty May 2024 — Genetic Resources + Traditional Knowledge.
  • MC12 Decision (17 June 2022) — COVID vaccines.
  • EFTA — Switzerland + Norway + Iceland + Liechtenstein.
  • Article 31bis (2017) — multilateral CL for export.